Eli Lilly places its bets beyond the weight-loss hype

Drugmakers have dominated headlines lately as DC presses for price restraint, obesity treatments fuel demand, and investors look for the next market leader as enthusiasm around Big Tech cools.

Against that noisy backdrop, Eli Lilly is making a pitch that it’s not just telling an obesity-drug story but also staking a claim in the broader Big Pharma growth cycle.

Moving beyond weight loss

Lilly’s blockbuster success with GLP-1 drugs like Mounjaro and Zepbound still drives the narrative around its stock. These two products alone generated half of the company’s 2025 revenue, which is both a strength and a risk.

And management knows it, as evidenced by a recent push to diversify.

Institutions are watching a few developing narratives:

• Q4 earnings beat expectations, with revenue up more than 40% year-over-year and EPS coming in above estimates.
• Lilly agreed to acquire Orna Therapeutics for $2.4 billion, adding early-stage therapies for autoimmune diseases like MS and rheumatoid arthritis.
• An expanded collaboration with Innovent Biologics could generate up to $8.5 billion in milestone payments and strengthen its oncology/immunology research.
• Hedge funds and large asset managers own more than 80% of the stock, and firms like Navellier & Associates recently increased their stakes.

Analysts at Bernstein and BMO see these moves as a hedge against a more competitive and politically sensitive obesity-drug market, where pricing pressure and patent disputes are already complicating the picture.

Wall Street looks for perspective

Market-watchers broadly agree Eli Lilly stock is expensive, but many argue the valuation reflects durability. Unlike smaller biotech or telehealth players tied to thin margins, Lilly controls manufacturing and pricing power.

Analysts also see upside from the company’s own oral obesity pill candidate, which could narrow Novo Nordisk’s early lead in that space.

Shares might not be cheap, but Lilly is trying to prove it’s not just a one-trick pony. Premium valuations can be justified when a company pairs dominant products and credible next-step plans. Time will tell if Eli Lilly belongs in that group.

The recent pullback in Eli Lilly stock is real, but it pales in comparison to the 61% gains over the past six months.

Analyst and telehealth bull Nick Moss recently offered his take on where Lilly and its biggest rival currently stand, via X.

“For those individuals that only speak AI… $NVO is the equivalent of $AMD in this ecosystem ($LLY = $NVDA). Both $LLY and $NVO are partnered with $WW and $LFMD… and yet these telehealth companies are priced for bankruptcy?”